Merck Insomnia Drug Shows Improvements; Filing On Track
This article was originally published in The Pink Sheet Daily
Merck is confident it can compete in the highly generic insomnia market; Phase III results show the insomnia drug suvorexant may have further benefits for patients.
You may also be interested in...
Merck reports second quarter earnings, looking past the patent expiration of Singulair to the drugs it icurrently is developing to replace the revenues it is expected to lose.
A data monitoring committee’s early termination of a 16,000-patient Phase III study of Merck’s cap-K inhibitor odanacatib suggests the osteoporosis therapy could have a competitive profile. Drug will need to offer significant advantages to cut it in the crowded market already saturated with generics.
Two of Merck’s potential near-term launches, suvorexant for insomnia and odanacatib for osteoporosis, will enter crowded markets dominated by generics, but executives at the Citi Global Health Care conference maintain that novel mechanisms of action will address unmet market opportunities.